


**AYRTON DRUG MANUFACTURING LTD**  
**Un-Audited Statement of Financial Position**  
**For the First Quarter Ending 30th September, 2017**

	30/09/2017 GHC	30/09/2016 GHC
<b>Non current assets</b>		
Property, plant and equipment	7,067,282	7,471,772
Intangible	8,950	42,430
	<u>7,076,232</u>	<u>7,514,202</u>
<b>Current assets</b>		
Inventories	11,403,738	10,277,131
Trade and other receivable	10,245,683	9,901,250
Amount due from Holding company	2,638,198	-
Income Tax Receivable	-	271,320
Cash and bank	300,436	836,849
<b>Total Current Assets</b>	<u>24,588,055</u>	<u>21,286,550</u>
<b>Total Assets</b>	<u><u>31,664,287</u></u>	<u><u>28,800,752</u></u>
<b>Equity and liabilities</b>		
<b>Equity</b>		
Issued capital	4,475,000	4,475,000
Other capital reserve	1,739,436	1,739,436
Income surplus	12,748,970	9,970,020
<b>Total equity</b>	<u>18,963,406</u>	<u>16,184,456</u>
<b>Non-current liabilities</b>		
Deferred tax	154,459	154,459
<b>Current liabilities</b>		
Trade and other payable	4,394,574	6,110,913
Amount due to holding company	1,036,406	1,033,337
Income tax payable	364,798	-
Short term borrowings	6,750,644	5,317,587
<b>Total Liabilities</b>	<u>12,700,881</u>	<u>12,616,296</u>
<b>Total Equity and liabilities</b>	<u><u>31,664,287</u></u>	<u><u>28,800,752</u></u>

Director  
Yaw Opare-Asamoah



Director  
Nik Amarteifio



NIK AMARTEIFIO

**AYRTON DRUG MANUFACTURING LTD****Un-Audited Statement of Profit or Loss and other Comprehensive****Income for the First Quarter Ending 30th September, 2017**

	30/09/2017	30/09/2016
	GHC	GHC
Revenue	9,003,091	9,132,709
Cost of sales	(4,244,877)	(4,648,132)
<b>Gross profit</b>	<b>4,758,214</b>	<b>4,484,578</b>
Other income	-	106,206
Selling and distribution costs	(931,207)	(1,426,697)
Administrative expenses	(2,180,262)	(1,826,529)
<b>Operating Profit/(loss)</b>	<b>1,646,745</b>	<b>1,337,559</b>
Finance costs	(423,142)	(342,075)
<b>Profit/(loss) before tax</b>	<b>1,223,603</b>	<b>995,483</b>
Income tax expense	(287,395)	(299,030)
<b>Profit/(loss) after tax</b>	<b>936,208</b>	<b>696,454</b>
No.of shares	<b>215,000,000</b>	<b>215,000,000</b>
<b>Earnings per share</b>	<b>0.0044</b>	<b>0.0032</b>

**Un-Audited Statement of Changes in Equity**  
**For the First Quarter Ending 30th September, 2017**

	<b>Stated capital GH¢</b>	<b>Retained Earnings GH¢</b>	<b>Other Reserves GH¢</b>	<b>Total GH¢</b>
Period ended 30th September, 2017				
<b>At 1 JULY 2017</b>	4,475,000	11,812,762	1,739,436	18,027,198
Profit/(Loss) for the period	-	936,208		936,208
Reversal during the period	-			-
<b>Balance as at 30th September, 2017</b>	<b>4,475,000</b>	<b>12,748,970</b>	<b>1,739,436</b>	<b>18,963,406</b>

	<b>Issued Capital GH¢</b>	<b>Income surplus GH¢</b>	<b>Other reserves GH¢</b>	<b>Total GH¢</b>
Period ended 30th September, 2016				
<b>At 1 JULY 2016</b>	4,475,000	9,273,567	1,739,436	15,488,003
<b>Profit/(Loss) for the period</b>		696,454		696,454
Reversal during the period				
<b>Balance as at 30th September, 2016</b>	<b>4,475,000</b>	<b>9,970,020</b>	<b>1,739,436</b>	<b>16,184,456</b>

